key: cord-0971539-p8mlvptm
authors: Alhazzani, Waleed; Alshahrani, Mohammed; Alshamsi, Fayez; Aljuhani, Ohoud; Eljaaly, Khalid; Hashim, Samaher; Alqahtani, Rakan; Alsaleh, Doaa; Al Duhailib, Zainab; Algethamy, Haifa; Al-Musawi, Tariq; Alshammari, Thamir; Alqarni, Abdullah; Khoujah, Danya; Tashkandi, Wail; Dahhan, Talal; Almutairi, Najla; Alserehi, Haleema A.; Al-Yahya, Maytha; Al-Judaibi, Bandar; Arabi, Yaseen M.; Abualenain, Jameel; Alotaibi, Jawaher M.; Al bshabshe, Ali; Alharbi, Reham; Al-Hameed, Fahad; Elhazmi, Alyaa; Almaghrabi, Reem S.; Almaghlouth, Fatma; Abedalthagafi, Malak; Al Khathlan, Noor; Al-Suwaidan, Faisal A.; Bunyan, Reem F.; Baw, Bandar; Alghamdi, Ghassan; Al Hazmi, Manal; Mandourah, Yasser; Assiri, Abdullah; Enani, Mushira; Alawi, Maha; Aljindan, Reem; Aljabbary, Ahmed; Alrbiaan, Abdullah; Algurashi, Fahd; Alsaawi, Abdulmohsen; Alenazi, Thamer H.; Alsultan, Mohammed A.; Alqahtani, Saleh A.; Memish, Ziad; Al-Tawfiq, Jaffar A.; Al-jedai, Ahmed
title: The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: therapy section
date: 2021-10-20
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2021.10.005
sha: 822b12491732660a61ec40829764852ae008e349
doc_id: 971539
cord_uid: p8mlvptm

BACKGROUND: The rapid increase in coronavirus disease 2019 (COVID-19) cases during the subsequent waves in Saudi Arabia and other countries prompted the Saudi Critical Care Society (SCCS) to put together a panel of experts to issue evidence-based recommendations for the management of COVID-19 in the intensive care unit (ICU). METHODS: The SCCS COVID-19 panel included 51 experts with expertise in critical care, respirology, infectious disease, epidemiology, emergency medicine, clinical pharmacy, nursing, respiratory therapy, methodology, and health policy. All members completed an electronic conflict of interest disclosure form. The panel addressed 9 questions that are related to the therapy of COVID-19 in the ICU. We identified relevant systematic reviews and clinical trials, then used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach as well as the evidence-to-decision framework (EtD) to assess the quality of evidence and generate recommendations. RESULTS: The SCCS COVID-19 panel issued 12 recommendations on pharmacotherapeutic interventions (immunomodulators, antiviral agents, and anticoagulants) for severe and critical COVID-19, of which 3 were strong recommendations and 9 were weak recommendations. CONCLUSION: The SCCS COVID-19 panel used the GRADE approach to formulate recommendations on therapy for COVID-19 in the ICU. The EtD framework allows adaptation of these recommendations in different contexts. The SCCS guideline committee will update recommendations as new evidence becomes available.

The rapid increase in coronavirus disease 2019 cases during the subsequent waves in Saudi Arabia and other countries prompted the Saudi Critical Care Society (SCCS) to put together a panel of experts to issue evidence-based recommendations for the management of COVID-19 in the intensive care unit (ICU).

The SCCS COVID-19 panel included 51 experts with expertise in critical care, respirology, infectious disease, epidemiology, emergency medicine, clinical pharmacy, nursing, respiratory therapy, methodology, and health policy. All members completed an electronic conflict of interest disclosure form. The panel addressed 9 questions that are related to the therapy of COVID-19 in the ICU. We identified relevant systematic reviews and clinical trials, then used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach as well as the evidence-to-decision framework (EtD) to assess the quality of evidence and generate recommendations.

The SCCS COVID-19 panel issued 12 recommendations on pharmacotherapeutic interventions (immunomodulators, antiviral agents, and anticoagulants) for severe and critical COVID-19, of which 3 were strong recommendations and 9 were weak recommendations.

The SCCS COVID-19 panel used the GRADE approach to formulate recommendations on therapy for COVID-19 in the ICU. The EtD framework allows adaptation of these The SCCS issued the first guidelines on the management of COVID-19 in the intensive care unit (ICU) in 2020 [1] . Given the rapid evolution of evidence in this field, updating the guidelines is crucial. Therefore, the SCCS, in collaboration with the Ministry of Health in Saudi Arabia, undertook this initiative aiming to produce trustworthy evidence-based practice guidelines focusing on therapy for COVID-19.

The scope of the current guideline is to provide recommendations to critical care teams on the management of adults with severe or critical COVID-19 in the ICU. We used simplified definition of severe and critical COVID-19 (Supplementary Table) .

The target users of this guideline are healthcare workers caring for COVID-19 patients in the ICU, including intensivists, emergency physicians, infectious diseases physicians, clinical pharmacists, nurses, respiratory therapists, and policymakers.

The chairs of the practice guidelines chapter under the SCCS selected panel members based on expertise with the aim to maintain gender and geographic balance. The panel included 51 members with collective expertise in critical care, infectious diseases, emergency medicine, clinical pharmacy, epidemiology, respiratory therapy, nursing, public health, clinical research and health policy and administration. We engaged representatives from different governmental and private healthcare sectors across the Kingdom of Saudi Arabia, including the Ministry of Health.

All authors completed an electronic WHO conflict of interest form, as previously outlined by Alhazzani et al. for the management of potential conflict of interest [2] .

With support from the GUIDE (Guidelines in Intensive Care, Development, and Evaluation) group, a professional medical librarian designed a search strategy of Cochrane Central and MEDLINE databases. The search is being updated on a monthly basis, and a dedicated systematic review team reviews titles and abstracts to identify relevant systematic reviews and randomized controlled trials (RCTs). For this guideline, we restricted the eligibility to only include relevant studies published in English prior to April 25, 2021.

When there are more than one RCT but no published meta-analysis on a specific question, we used a random-effects model meta-analysis to pool effect sizes across RCTs. We presented the results as relative risk (RR) and 95 % confidence interval (CI) for binary outcomes and mean difference (MD) and 95% CI for continuous outcomes. For recommendations informed by data from published systematic reviews, we used the estimates reported by study authors (Supplement).

We used the GRADE approach to assess the quality of the body of evidence [3, 4] .

Methodologists rated the quality of evidence as high, moderate, low, or very low [5] , and used the GRADEpro GDT (guideline development tool) online software (https://gradepro.org/) to produce the evidence summaries [6] . We only used direct evidence from COVID-19 population to inform our recommendations.

For every recommendation, we used the EtD framework to craft the recommendations. We included all recommendations-specific EtDs in the supplement. Panel members completed the J o u r n a l P r e -p r o o f EtD forms for each recommendation online. The methodologist used feedback and input from panel members to refine the judgment on EtD forms and craft the recommendations. In accordance with the GRADE taxonomy, we used the wording "we recommend" to express strong recommendations and "we suggest" to express weak recommendations. We present a summary of the guideline's recommendations in Table 1 and Figure 1 .

Immunomodulation therapy [10] .

Corticosteroid therapy in critically ill patients appears to have an acceptable safety profile. A large cohort study found a small increase in adverse events like gastrointestinal bleeding, sepsis, and heart failure with a short course of corticosteroids in an outpatient setting [11] . Additionally, the meta-analysis of COVID-19 corticosteroid trials showed no increase in the risk of adverse events with corticosteroid therapy [10] . Given that corticosteroids are inexpensive and widely available, this recommendation would increase equity and likely be an acceptable intervention to key stakeholders (Supplementary Table) . Hence, the panel issued a strong recommendation for using corticosteroids in ICU COVID-19 patients.

There are several questions that remained unanswered. Some panelists felt that higher doses of corticosteroids might be warranted in selected patients with features of acute respiratory distress syndrome or those with organizing pneumonia features on radiological imaging, however; current data demonstrate no definitive subgroup effect suggesting that further studies are needed.

Our recommendation is consistent with the Surviving Sepsis Campaign guidelines and the WHO guidelines [12, 13] . The National Institute of Health (NIH) guidelines recommend dexamethasone plus remdesivir (based on theoretical considerations) for those who require an increased amount of oxygen (within 24 hours of admission) without mechanical ventilation and recommend dexamethasone alone for those who require invasive mechanical ventilation or extracorporeal membrane oxygenation [14] . The Infectious Disease Society of America (IDSA) guidelines recommend dexamethasone for critically ill patients and suggest dexamethasone for severe COVID-19 [15] .

There is limited evidence regarding the optimal dosing, timing, duration, and steroids type. The effect of all these variables on mortality and other outcomes needs to be further assessed in clinical trials. However, the panel issued a weak recommendation favoring the use of dexamethasone over other corticosteroids as it was the only agent studied in the largest trial to date.

Question: Should tocilizumab vs. no tocilizumab be used for severe or critical COVID-19?

1. For adults with COVID-19 who are receiving high-flow nasal cannula (HFNC) or noninvasive ventilation (NIV) in the ICU, the panel suggests using tocilizumab over not using it (weak recommendation, low quality evidence).

J o u r n a l P r e -p r o o f Studies shown benefit of tocilizumab when used concomitantly with corticosteroids in patients with elevated C-reactive protein (CRP) >75 mg/l, or when tocilizumab therapy was initiated within 24 hours of ICU admission.

2. Due to insufficient evidence, we were unable to issue a recommendation for or against the use of tocilizumab in invasively ventilated COVID-19 patients. If clinicians decide to use tocilizumab in this context, it is probably best to use it within 24 hours of admission and/or in patients with CRP level >75 mg/l.

Interleukin-6 (IL-6) is a pleiotropic cytokine with both proinflammatory and anti-inflammatory effects, and IL-6-related cytokine storm has been proposed as a major target for the treatment of Table) . However, these results need to be interpreted with caution as tocilizumab is often used with other medications potentially increasing the risk of infection such as corticosteroids. In addition, higher quality evidence from the rheumatoid arthritis literature showed an increased risk of infection [30, 31] .

Considering the moderate quality evidence of mortality reduction in non-intubated COVID-19

patients and possible reduction in serious adverse effects, the panel issued a weak recommendation for the use of tocilizumab to treat severe COVID-19 (Supplementary Table) . 

Considering the low quality evidence, unclear effect on mortality, and the associated large cost of the intervention (Supplementary Table) , the panel issued a weak recommendation against the routine use of baricitinib in combination with remdesivir in adults with critical or severe COVID-19. However, the panel felt that the use of combination therapy in selected cases requiring HFNC or NIV who are unable receive corticosteroids or tocilizumab is reasonable.

The NIH suggested using combination therapy of baricitinib and remdesivir when corticosteroids cannot be used in non-intubated patients requiring oxygen supplementation [14] . A similar conditional recommendation was issued by the IDSA in their most recent updated guidelines [15] . The addition of baricitinib to corticosteroids remains controversial and needs to be studied further in randomized trials.

Question: Should convalescent plasma vs. no convalescent plasma be used for severe or critical COVID-19?

For adults with severe or critical COVID-19 in the ICU, the panel recommends against using convalescent plasma (strong recommendation, moderate quality evidence).

Convalescent plasma (obtained from patients who recovered from COVID-19) has been used to treat severe and critical COVID-19 patients despite the lack of RCTs confirming its benefit.

Recently, several RCTs have been published [37, 38] , the results of which have been summarized in a systematic review and meta-analysis including 1,060 patients with COVID-19

J o u r n a l P r e -p r o o f [39] . Table) .

Post-infusion adverse events, such as transfusion-related circulatory overload and acute lung injury were not consistently captured in randomized trials. Additionally, convalescent plasma requires plasmapheresis to collect samples from donors, which is of significant cost and not widely available.

Considering the lack of benefit found in randomized trials, overall moderate quality evidence, associated costs, feasibility issues, and the availability of other effective alternatives, we issued a strong recommendation against using convalescent plasma in patients with COVID-19 in the ICU (Supplementary Table) . Our recommendation is consistent with other published guidelines [13] [14] [15] . 

Intravenous immunoglobulin, a human blood product containing polyclonal immunoglobulin gamma, may improve passive immunity and modulate the hyperinflammatory response in COVID-19 patients through several proposed mechanisms including blocking proinflammatory cytokines as well as neutrophil activation [40, 41] .

We identified 3 relevant RCTs (n = 176) that compared the use of IVIG to placebo in patients with severe COVID-19 [42] [43] [44] . Doses of IVIG and standard of care varied between trials as follows: the first study enrolled 59 patients, comparing 20 g IVIG daily for 3 days to a placebo [42] . The second study enrolled 84 patients and used 400 mg/kg of IVIG daily for 3 days, in addition to using HCQ and lopinavir/ritonavir in both groups [44] . The third study enrolled 33 patients and used 0.5 g/kg of IVIG daily for 3 days in addition to methylprednisolone [43] .

We identified a phase 2 RCT (n=100) comparing IVIG to standard of care; however, this study focused on mild-to-moderate disease and only a few patients were admitted to the ICU, hence, it was not included in the quantitative analysis [45] .

We undertook a meta-analysis pooling the effect sizes across the eligible studies ( Supplementary   Figure) . Immunoglobulin use did not reduce risks of death (RR 0. 66 

Only one trial reported on the safety of IVIG in COVID-19 [45] . However, indirect evidence from use in other conditions showed a good safety profile, with few adverse effects (e.g., chills, headache, low-grade fever, nausea, vomiting, self-limited aseptic meningitis) [46] . IVIG is expensive and is not widely available. Furthermore, we could not find data on cost-effectiveness.

Considering the low quality evidence, unclear effect on patient-important outcomes, associated cost, and availability and feasibility issues, the panel issued a weak recommendation against the routine use of IVIG in critical COVID-19 outside clinical trials. Our recommendation should not be applied to patients on IVIG for other medical conditions. Additionally, IVIG may have some role in neurological complications such as COVID-19-related encephalomyelitis, neuropathy, and demyelinating neuropathies. Our recommendation is consistent with NIH guidelines [14] .

More clinical trials are needed to assess the safety and efficacy of IVIG in critical COVID-19.

For mechanically ventilated adults with critical COVID-19, we suggest against using remdesivir outside the context of clinical trials (weak recommendation, low quality evidence).

Remdesivir (GS-5734) is a broad-spectrum antiviral agent and a prodrug of its parent adenosine analog, GS-441524 [47] . 

Favipiravir is a selective RNA polymerase enzyme inhibitor which can prevent replication of the viral genome and has shown wide range of antiviral activity against different influenza viruses [53] [54] [55] .

Our search identified two systematic reviews and meta-analyses that summarized the results of RCTs on favipiravir in hospitalized COVID-19 patients [56, 57] . The most recent preprint systematic review and meta-analysis included 9 RCTs (n=827) comparing favipiravir to any other intervention; out of those, only 3 studies compared favipiravir to usual care or placebo. [58] [59] [60] . Two studies reported no effect of favipiravir on the need for ICU transfer compared to controls J o u r n a l P r e -p r o o f [60, 63] . Nausea, vomiting, diarrhea, and elevated uric acid and liver transaminases were the most commonly reported adverse events of favipiravir [59, [61] [62] [63] [64] [65] .

Studies were at high risk of bias. Moreover, the studies included different comparative arms, had small sample sizes, and used different dosing and duration of favipiravir therapy. Therefore, the overall quality of this indirect evidence is very low. There are however, several registered RCTs 

Question: Should HCQ vs. no HCQ be used for severe or critical COVID-19?

For adults with severe or critical COVID-19 in the ICU, the panel recommends against using HCQ (strong recommendation, moderate quality evidence).

Few studies showed in vitro activity of HCQ against SARS-CoV-2. The long clinical experience, its wide availability, low cost, and relative safety compared to chloroquine encouraged the use of HCQ for COVID-19 therapy early in the pandemic [15, 66] .

We identified a systematic review and meta-analysis summarizing 26 RCTs (n=10,012) on HCQ in COVID-19 [67] . While most trials were small, the evidence from cumulative meta-analysis was dominated by the RECOVERY and the SOLIDARITY trials [51, 68] . Both trials used HCQ in higher doses than all other trials except REMAP-CAP [67] . The meta-analysis revealed no Table. Considering the moderate quality evidence of no mortality benefit (and possible harm), and the associated serious adverse events, the panel issued a strong recommendation against using HCQ to treat critical COVID-19 cases (Supplementary Table) . Our recommendation is consistent with most prominent international guidelines [13] [14] [15] . Additional studies on the role of HCQ in critical COVID-19 are probably not needed and future research should be focused on other therapeutic options.

For adults with critical COVID-19 and no clinical suspicion of venous thromboembolism (VTE), we suggest using prophylactic dosing anticoagulation over therapeutic anticoagulation (weak recommendation, low quality evidence).

This recommendation does not apply to patients with high suspicion of (or confirmed) acute VTE or those with other indications for therapeutic anticoagulation.

The rates of arterial thrombosis and VTE in COVID-19 patients are variable but reported to be higher than in non-COVID-19 patients. A systematic review and meta-analysis of 11 observational studies showed VTE rates around 23.9% (95% CI 16.2% to 33.7%) despite prophylactic anticoagulation [69] . The rate of pulmonary embolism is relatively high in ICU COVID-19 patients (15%; 95% CI 9 to 25%) [69] . Similarly, the rates of arterial thrombosis such as myocardial infarction and stroke are high in ICU COVID-19 patients (13.9% and 3.7%, respectively) [70] . [71] . Recruitment was terminated for futility after an interim analysis of 1,074 patients. However, therapeutic anticoagulation reduced major thrombotic events (5.7% versus 10.3%, low quality) and resulted in a small increase in the risk of major bleeding (3.1% versus 2.4%, low quality) [71] .

These trials have several limitations: the quality of evidence is tempered by lack of blinding, high dropout rate (>10%), and early termination of recruitment. Therefore, the overall quality of evidence was judged to be low (Supplementary Table) . In addition, the trials did not focus on highrisk patients such as those with elevated D-dimer levels [70, 72] .

Considering the lack of clear benefit, the potential for harm, and the low quality of evidence, the panel issued a weak recommendation favoring the use of prophylaxtic dosing VTE prophylaxis over therapeutic anticoagulation in COVID-19 patients. Our recommendation is similar to that of the American Society of Hematology [73] . In patients with D-dimer above 10,000 ng/ml [70] , clinicians might need to rule out VTE, however, the optimal approach to address this problem is unclear. There remains uncertainty about using D-dimer levels to guide therapeutic decisions; that could be further studied in future research.

J o u r n a l P r e -p r o o f

The SCCS Guidelines Chapter members will meet monthly to discuss new evidence on relevant topics to this guideline. We plan to update recommendations in view of new evidence that would likely result in changing the recommendation strength and/or direction.

The SCCS COVID-19 panel included 51 experts with expertise in critical care, respirology, infectious disease, epidemiology, emergency medicine, clinical pharmacy, nursing, respiratory therapy, methodology, and health policy. The panel addressed 9 questions that are related to the therapy of COVID-19 in the ICU. We used the GRADE approach and the evidence-to-decision framework (EtD) to generate recommendations.

The SCCS COVID-19 panel issued 12 recommendations on pharmacotherapeutic interventions for severe and critical COVID-19, of which 3 were strong recommendations and 9 were weak recommendations.

There are several strengths of these guidelines. The guidelines were developed using rigorous methodology, including comprehensive evidence synthesis and assessment, application of robust tools to allow reproducibility of the guidelines, and selecting panel members with attention to clinical, gender, and geographic diversity.

Although some members of the panel have suffered from COVID-19 and recovered, we did not formally include patient representatives in the guideline development process.

The SCCS COVID-19 recommendations can be used to facilitate evidence-based clinical decisions at the bedside. Additionally, the EtD framework allows adaptation of these J o u r n a l P r e -p r o o f

Not applicable

Copyright is transferred to the publisher in case of acceptance. The corresponding author had full access to all data presented and the final responsibility of deciding to submit the study for publication.

All data produced and analyzed in this study are included in this article in Table 1 , Figure 1 and supplement material.

All panel members completed the WHO declaration forms; none of the panel members declared any financial conflicts relevant to this guideline. Dr Waleed Alhazzani is a co-chair of the surviving sepsis campaign COVID-19 guidelines and member of the GRADE Working Group, Dr Yaseen Arabi is a co-investigator on REMAP-CAP trial.

The production of this guideline did not receive grant from any funding agency in the public, commercial or nonprofit sectors. 

Should therapeutic anticoagulation vs. prophylactic dose anticoagulation be used for critical COVID-19?

12. For adults with critical COVID-19 and no clinical suspicion of venous thromboembolism (VTE), we suggest using prophylactic dosing anticoagulation over therapeutic anticoagulation Remark:

This recommendation does not apply to patients with high suspicion of acute VTE or those with other indications for therapeutic anticoagulation.

Weak recommendation, low quality evidence.

The saudi critical care society clinical practice guidelines on the management of COVID-19 patients in the intensive care unit

Conflicts of interest disclosure forms and management in critical care clinical practice guidelines

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

GRADE guidelines: 3. Rating the quality of evidence

GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations

GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes

Clinical features and 9

Dexamethasone in Hospitalized Patients with Covid-19

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

Association Between Oral Corticosteroid Bursts and Severe Adverse Events : A Nationwide Population-Based Cohort Study

A living WHO guideline on drugs for covid-19

Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update

COVID-19 Treatment Guidelines Panel. Coronavirus Disease

Treatment Guidelines. National Institutes of Health

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial

FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Tocilizumab in Hospitalized Patients with Severe Covid-19

Tocilizumab in Patients Hospitalized with Covid-19

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials

Hlh Across Speciality Collaboration UK: COVID-19: consider cytokine storm syndromes and immunosuppression

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19

COVID-19: combining antiviral and anti-inflammatory treatments

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Metaanalysis

Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection

Evaluation of the Effect of Intravenous Immunoglobulin Dosing on Mortality in Patients with Sepsis: A Network Metaanalysis

The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial

Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease

Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial

A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in COVID-19 patients with Regular Intravenous Immunoglobulin Therapy

Recommended indications for the administration of polyclonal immunoglobulin preparations

GS-441524 as therapeutic options for coronaviruses

Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2

The journey of remdesivir: from Ebola to COVID-19

Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Remdesivir for severe covid-19: a clinical practice guideline

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice

vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and

A(H1N1) viruses

Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis

The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study

Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients

Hydroxychloroquine safety: A metaanalysis of randomized controlled trials

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Venous Thromboembolism among Hospitalized Patients with COVID-19

Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Therapeutic Anticoagulation in Critically Ill Patients with Covid-19 -Preliminary Report

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

recommendations to different contexts. The SCCS guideline committee will update recommendations as new evidence becomes available. 3. For adults with COVID-19 who are receiving highflow nasal cannula or noninvasive ventilation, the panel suggests using tocilizumab over not using it

Studies shown benefit of tocilizumab when used concomitantly with corticosteroids in patients with elevated C-reactive protein (CRP) >75 mg/l, or when tocilizumab therapy was initiated within 24 hours of ICU admission.Weak recommendation, low quality evidence.4. Due to insufficient evidence, we were unable to issue a recommendation for or against the use of tocilizumab in invasively ventilated COVID-19 patients. If clinicians decide to use tocilizumab in this context, it is probably better to use it early (within 24 hours of admission) and/or in patients with CRP level >75 mg/l.